Pharmaceutical manufacturer discount card usage by government program beneficiaries has been an active area for government action in recent years.
The influential Medicare Payment Advisory Commission (MedPAC) has voted to recommend to Congress in its March report that Medicare Part B drug payment rates for 340B drugs be reduced by 10 percent for hospitals participating in the 340B Drug Pricing Program (340B Program).
The Times Herald-Record’s recordonline.com reported that Elant Inc.’s civil settlement with NY will not protect them from criminal prosecution for Medicare and Medicaid fraud.
Congress chose to end 2015 with some last-minute Medicare reforms impacting healthcare providers.
The Senate Finance Committee chronic care working group recently released a Policy Options Document continuing an effort that started with a hearing titled, “Chronic Illness: Addressing Patients’ Unmet Needs” in the summer of 2014.
By now, providers are very familiar with Medicare recovery audit contractors, or RACs – the private companies who have authority to review medical records at a moment’s notice.
With the advent of the 2016 (Happy New Year!), hospices now face the revised hospice payment system.
On December 15, 2015, Congressional leaders released the text of sweeping spending and tax proposals that include a number of provisions impacting Medicare and the ACA, among many others.
For those unsure or unaware, Medicare and Medicaid are both government health insurance programs.
OIG Proposes Alternative Part B Payment Methodologies for 340B Drugs: Is This the End of 340B As We Know It?
Last week, under the cover of the impending Thanksgiving Holiday, OIG lobbed another grenade at the 340B Drug Discount Program.